论文信息 - The FDA drug safety surveillance program: adverse event reporting trends. - 字舞流文

The FDA drug safety surveillance program: adverse event reporting trends.

Stephanie Chung | Gaurav Deshpande | Victor Gogolak | Sheila Weiss-Smith | G. Deshpande | Sheila Weiss-Smith | S. Chung | Victor Gogolak

[1] D. Cherry,et al. National Ambulatory Medical Care Survey: 2000 summary. , 2002, Advance data.

[2] D. Cherry,et al. National Ambulatory Medical Care Survey: 2005 summary. , 2007, Advance data.

[3] T. J. Moore,et al. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. , 2007, Archives of internal medicine.

[4] D J Graham,et al. The role of databases in drug postmarketing surveillance , 2001, Pharmacoepidemiology and drug safety.

[5] D. Wysowski,et al. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. , 2005, Archives of internal medicine.